ProPhase Labs Inc (PRPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProPhase Labs Inc (PRPH) has a cash flow conversion efficiency ratio of -3.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.52 Million) by net assets ($6.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can ProPhase Labs Inc fund operations to measure how many days the company can operate on defensive assets alone.
ProPhase Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how ProPhase Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProPhase Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProPhase Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Imobiliária Construtora Grão Pará S.A.
LS:GPA
|
0.000x |
|
BLUERUSH Media Group Corp
V:BTV
|
-0.015x |
|
Vaxil Bio Ltd
V:VXL
|
-0.042x |
|
Reco International Group Inc
V:RGI
|
0.037x |
|
Amigo Holdings PLC
LSE:AMGO
|
N/A |
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
-0.751x |
|
Empresa Distribuidora Electrica Regional SA
BA:EMDE
|
0.011x |
|
Abingdon Health Plc
LSE:ABDX
|
-0.181x |
Annual Cash Flow Conversion Efficiency for ProPhase Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of ProPhase Labs Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see PRPH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.35 Million | $-17.54 Million | -2.385x | -937.94% |
| 2023-12-31 | $49.38 Million | $-11.35 Million | -0.230x | -151.21% |
| 2022-12-31 | $63.63 Million | $28.55 Million | 0.449x | +293.16% |
| 2021-12-31 | $58.63 Million | $-13.62 Million | -0.232x | +5.40% |
| 2020-12-31 | $10.56 Million | $-2.59 Million | -0.246x | -227.91% |
| 2019-12-31 | $11.23 Million | $-841.00K | -0.075x | +41.68% |
| 2018-12-31 | $16.50 Million | $-2.12 Million | -0.128x | -49.70% |
| 2017-12-31 | $33.09 Million | $-2.84 Million | -0.086x | -8.34% |
| 2016-12-31 | $5.96 Million | $-472.00K | -0.079x | +80.01% |
| 2015-12-31 | $8.83 Million | $-3.50 Million | -0.396x | -31.98% |
| 2014-12-31 | $10.72 Million | $-3.22 Million | -0.300x | -432.47% |
| 2013-12-31 | $12.60 Million | $1.14 Million | 0.090x | +118.04% |
| 2012-12-31 | $11.45 Million | $-5.73 Million | -0.500x | -166.43% |
| 2011-12-31 | $11.23 Million | $-2.11 Million | -0.188x | +28.78% |
| 2010-12-31 | $13.46 Million | $-3.55 Million | -0.264x | -933.02% |
| 2009-12-31 | $14.06 Million | $445.00K | 0.032x | +118.40% |
| 2008-12-31 | $17.77 Million | $-3.06 Million | -0.172x | -205.56% |
| 2007-12-31 | $23.30 Million | $-1.31 Million | -0.056x | -250.57% |
| 2006-12-31 | $25.59 Million | $956.94K | 0.037x | -77.76% |
| 2005-12-31 | $25.37 Million | $4.27 Million | 0.168x | -20.79% |
| 2004-12-31 | $21.96 Million | $4.66 Million | 0.212x | +556.59% |
| 2003-12-31 | $20.79 Million | $-966.23K | -0.046x | -257.52% |
| 2002-12-31 | $18.42 Million | $543.64K | 0.030x | +156.01% |
| 2001-12-31 | $21.20 Million | $-1.12 Million | -0.053x | +40.24% |
| 2000-12-31 | $21.21 Million | $-1.87 Million | -0.088x | -277.69% |
| 1999-12-31 | $26.20 Million | $1.30 Million | 0.050x | -75.14% |
| 1998-12-31 | $44.60 Million | $8.90 Million | 0.200x | -7.54% |
| 1997-12-31 | $41.70 Million | $9.00 Million | 0.216x | +123.54% |
| 1996-12-31 | $1.20 Million | $-1.10 Million | -0.917x | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more